Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life
IntroductionEpidermal barrier dysfunction in children with atopic dermatitis can cause transcutaneous sensitization to allergens and allergic diseases. We evaluated the effectiveness of an early-intervention algorithm for atopic dermatitis treatment, utilizing pimecrolimus for long-term maintenance...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2023.1102354/full |
| _version_ | 1797839958912794624 |
|---|---|
| author | Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Leyla S. Namazova-Baranova Leyla S. Namazova-Baranova Svetlana G. Makarova Roman A. Ivanov Stepan G. Grigorev Stepan G. Grigorev Dmitri V. Fedorov Eduard T. Ambarchian Eduard T. Ambarchian Roman V. Epishev Roman V. Epishev Alexander I. Materikin Leonid A. Opryatin Alena A. Savelova |
| author_facet | Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Leyla S. Namazova-Baranova Leyla S. Namazova-Baranova Svetlana G. Makarova Roman A. Ivanov Stepan G. Grigorev Stepan G. Grigorev Dmitri V. Fedorov Eduard T. Ambarchian Eduard T. Ambarchian Roman V. Epishev Roman V. Epishev Alexander I. Materikin Leonid A. Opryatin Alena A. Savelova |
| author_sort | Nikolay N. Murashkin |
| collection | DOAJ |
| description | IntroductionEpidermal barrier dysfunction in children with atopic dermatitis can cause transcutaneous sensitization to allergens and allergic diseases. We evaluated the effectiveness of an early-intervention algorithm for atopic dermatitis treatment, utilizing pimecrolimus for long-term maintenance therapy, in reducing transcutaneous sensitization in infants.MethodThis was a single-center cohort observational study that enrolled children aged 1-4 months with family history of allergic diseases, moderate-to-severe atopic dermatitis, and sensitization to ≥ 1 of the investigated allergens. Patients who sought medical attention at atopic dermatitis onset (within 10 days) were group 1 “baseline therapy with topical glucocorticoids with subsequent transition to pimecrolimus as maintenance therapy”; patients who sought medical attention later were group 2 “baseline and maintenance therapy with topical glucocorticoids, without subsequent use of pimecrolimus”. Sensitization class and level of allergen-specific immunoglobulin E were determined at baseline, and 6 and 12 months of age. Atopic dermatitis severity was evaluated using the Eczema Area and Severity Index score at baseline and 6, 9 and 12 months of age.ResultsFifty-six and 52 patients were enrolled in groups 1 and 2, respectively. Compared with group 2, group 1 demonstrated a lower level of sensitization to cow's milk protein, egg white and house dust mite allergen at 6 and 12 months of age, and a more pronounced decrease in atopic dermatitis severity at 6, 9 and 12 months of age. No adverse events occurred.DiscussionThe pimecrolimus-containing algorithm was effective in treating atopic dermatitis and prophylaxis of early forms of allergic diseases in infants.Trial registrationhttps://clinicaltrials.gov/NCT04900948, retrospectively registered, 25 May 2021. |
| first_indexed | 2024-04-09T16:06:39Z |
| format | Article |
| id | doaj.art-b2b449050edb481f9c9a9aea6f116733 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-09T16:06:39Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-b2b449050edb481f9c9a9aea6f1167332023-04-25T05:55:02ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602023-04-011110.3389/fped.2023.11023541102354Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of lifeNikolay N. Murashkin0Nikolay N. Murashkin1Nikolay N. Murashkin2Nikolay N. Murashkin3Leyla S. Namazova-Baranova4Leyla S. Namazova-Baranova5Svetlana G. Makarova6Roman A. Ivanov7Stepan G. Grigorev8Stepan G. Grigorev9Dmitri V. Fedorov10Eduard T. Ambarchian11Eduard T. Ambarchian12Roman V. Epishev13Roman V. Epishev14Alexander I. Materikin15Leonid A. Opryatin16Alena A. Savelova17National Medical Research Center for Children’s Health, Moscow, RussiaSechenov First Moscow State Medical University (Sechenov University), Moscow, RussiaCentral State Medical Academy of the Presidential Administration of the Russian Federation, Moscow, RussiaResearch Institute for Pediatrics and Children’s Health Protection, Federal National Public Healthcare Institution “Central Clinical Hospital of the Russian Academy of Sciences”, Ministry of Science and Higher Education, Moscow, RussiaResearch Institute for Pediatrics and Children’s Health Protection, Federal National Public Healthcare Institution “Central Clinical Hospital of the Russian Academy of Sciences”, Ministry of Science and Higher Education, Moscow, RussiaPirogov Russian National Research Medical University, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaKirov Military Medical Academy, St Petersburg, RussiaPediatric Infectious Disease Clinical Research Center of the Federal Medical Biological Agency, St Petersburg, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaResearch Institute for Pediatrics and Children’s Health Protection, Federal National Public Healthcare Institution “Central Clinical Hospital of the Russian Academy of Sciences”, Ministry of Science and Higher Education, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaResearch Institute for Pediatrics and Children’s Health Protection, Federal National Public Healthcare Institution “Central Clinical Hospital of the Russian Academy of Sciences”, Ministry of Science and Higher Education, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaNational Medical Research Center for Children’s Health, Moscow, RussiaIntroductionEpidermal barrier dysfunction in children with atopic dermatitis can cause transcutaneous sensitization to allergens and allergic diseases. We evaluated the effectiveness of an early-intervention algorithm for atopic dermatitis treatment, utilizing pimecrolimus for long-term maintenance therapy, in reducing transcutaneous sensitization in infants.MethodThis was a single-center cohort observational study that enrolled children aged 1-4 months with family history of allergic diseases, moderate-to-severe atopic dermatitis, and sensitization to ≥ 1 of the investigated allergens. Patients who sought medical attention at atopic dermatitis onset (within 10 days) were group 1 “baseline therapy with topical glucocorticoids with subsequent transition to pimecrolimus as maintenance therapy”; patients who sought medical attention later were group 2 “baseline and maintenance therapy with topical glucocorticoids, without subsequent use of pimecrolimus”. Sensitization class and level of allergen-specific immunoglobulin E were determined at baseline, and 6 and 12 months of age. Atopic dermatitis severity was evaluated using the Eczema Area and Severity Index score at baseline and 6, 9 and 12 months of age.ResultsFifty-six and 52 patients were enrolled in groups 1 and 2, respectively. Compared with group 2, group 1 demonstrated a lower level of sensitization to cow's milk protein, egg white and house dust mite allergen at 6 and 12 months of age, and a more pronounced decrease in atopic dermatitis severity at 6, 9 and 12 months of age. No adverse events occurred.DiscussionThe pimecrolimus-containing algorithm was effective in treating atopic dermatitis and prophylaxis of early forms of allergic diseases in infants.Trial registrationhttps://clinicaltrials.gov/NCT04900948, retrospectively registered, 25 May 2021.https://www.frontiersin.org/articles/10.3389/fped.2023.1102354/fullatopic dermatitischildrensensitizationfood allergensindoor allergenspimecrolimus |
| spellingShingle | Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Nikolay N. Murashkin Leyla S. Namazova-Baranova Leyla S. Namazova-Baranova Svetlana G. Makarova Roman A. Ivanov Stepan G. Grigorev Stepan G. Grigorev Dmitri V. Fedorov Eduard T. Ambarchian Eduard T. Ambarchian Roman V. Epishev Roman V. Epishev Alexander I. Materikin Leonid A. Opryatin Alena A. Savelova Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life Frontiers in Pediatrics atopic dermatitis children sensitization food allergens indoor allergens pimecrolimus |
| title | Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| title_full | Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| title_fullStr | Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| title_full_unstemmed | Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| title_short | Observational study of pimecrolimus 1% cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| title_sort | observational study of pimecrolimus 1 cream for prevention of transcutaneous sensitization in children with atopic dermatitis during their first year of life |
| topic | atopic dermatitis children sensitization food allergens indoor allergens pimecrolimus |
| url | https://www.frontiersin.org/articles/10.3389/fped.2023.1102354/full |
| work_keys_str_mv | AT nikolaynmurashkin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT nikolaynmurashkin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT nikolaynmurashkin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT nikolaynmurashkin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT leylasnamazovabaranova observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT leylasnamazovabaranova observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT svetlanagmakarova observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT romanaivanov observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT stepanggrigorev observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT stepanggrigorev observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT dmitrivfedorov observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT eduardtambarchian observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT eduardtambarchian observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT romanvepishev observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT romanvepishev observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT alexanderimaterikin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT leonidaopryatin observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife AT alenaasavelova observationalstudyofpimecrolimus1creamforpreventionoftranscutaneoussensitizationinchildrenwithatopicdermatitisduringtheirfirstyearoflife |